genprowebdirectory
Facebook Linkedin RSS Twitter Youtube
  • GEN Edge
    • Featured News
    • Multimedia
  • News
    • Insights
  • Topics
    • Artificial Intelligence
    • Bioprocessing
    • Cancer
    • Drug Discovery
    • Genome Editing
    • Infectious Diseases
    • OMICs
    • Translational Medicine
  • Magazine
    • Browse Issues
    • Subscribe
  • Multimedia
    • Summits
    • Webinars
    • GEN Live
    • Learning Labs
    • Podcasts
  • Resources
    • A-Lists
    • eBooks/Perspectives
    • Tutorials
    • Peer-Reviewed Journals
      • GEN Biotechnology
      • Re:Gen Open
    • New Products
    • Conference Calendar
  • Subscribe
    • Get GEN Magazine
    • Get GEN eNewsletters
Search
Facebook Linkedin RSS Twitter Youtube
Sign in
Welcome! Log into your account
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
A password will be e-mailed to you.
Genetic Engineering & Biotechnology News GEN – Genetic Engineering and Biotechnology News
Genetic Engineering & Biotechnology News Genetic Engineering & Biotechnology News
  • GEN Edge
    • Featured News
    • Multimedia
  • News
    • Insights
  • Topics
    • Artificial Intelligence
    • Bioprocessing
    • Cancer
    • Drug Discovery
    • Genome Editing
    • Infectious Diseases
    • OMICs
    • Translational Medicine
  • Magazine
    • Browse Issues
    • Subscribe
  • Multimedia
    • Summits
    • Webinars
    • GEN Live
    • Learning Labs
    • Podcasts
  • Resources
    • A-Lists
    • eBooks/Perspectives
    • Tutorials
    • Peer-Reviewed Journals
      • GEN Biotechnology
      • Re:Gen Open
    • New Products
    • Conference Calendar
  • Subscribe
    • Get GEN Magazine
    • Get GEN eNewsletters
Home 2024

Grail

StockWatch: “Final Resolution” Set for Illumina’s Grail Saga
GEN Edge

StockWatch: “Final Resolution” Set for Illumina’s Grail Saga

JPM: Illumina’s New CEO Spells Out 2024 Priorities, Presents Preliminary Q4, 2023 Results
GEN Edge

JPM: Illumina’s New CEO Spells Out 2024 Priorities, Presents Preliminary Q4, 2023 Results

StockWatch: Illumina Shares Climb Back after Tailspin from Q3 Results
GEN Edge

StockWatch: Illumina Shares Climb Back after Tailspin from Q3 Results

Illumina to Divest of Grail after Appeals Court Defeat
News

Illumina to Divest of Grail after Appeals Court Defeat

Illumina Links Grail Divestiture to Losing European Or U.S. Appeals
Industry News

Illumina Links Grail Divestiture to Losing European Or U.S. Appeals

European Commission Orders Illumina to Divest of Grail
Industry News

European Commission Orders Illumina to Divest of Grail

Illumina Vows Appeal of $479M Fine for Acquiring Grail before EC Approval
News

Illumina Vows Appeal of $479M Fine for Acquiring Grail before EC Approval

StockWatch: FTC vs. Amgen-Horizon Could Slam Brakes on Biotech M&A
Drug Discovery

StockWatch: FTC vs. Amgen-Horizon Could Slam Brakes on Biotech M&A

AACR News: GRAIL Validates Methylation-Based Cancer Detection Test
Cancer

AACR News: GRAIL Validates Methylation-Based Cancer Detection Test

StockWatch: Illumina Shares Steady as Icahn Escalates Proxy Fight
GEN Edge

StockWatch: Illumina Shares Steady as Icahn Escalates Proxy Fight

12Page 1 of 2

Read the Digital Edition

June 2024 cover

Explore

  • About GEN
  • Contact GEN
  • GEN Staff
  • Editorial Guidelines
  • Reprints and Permissions
  • Scientific Advisory Board

Advertise

  • Media Kit and Planning Calendar
  • Advertising Terms and Conditions

Resources

  • Get the GEN Magazine
  • Get the GEN Email Newsletter
  • Inside Precision Medicine
  • Privacy Policy
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.
Scroll Up